가격 및 재고 정보를 현재 이용할 수 없음 고객지원팀으로 연락바랍니다.
추천 제품
제품명
TSKgel® SuperSW mAb HR HPLC Column, phase diol, L × I.D. 30 m × 7.8 mm, 4 μm particle size
material
stainless steel
Agency
suitable for USP L20
suitable for USP L59
제품 라인
TSKgel®
제조업체/상표
Tosoh SuperSW mAb HR, 22854
파라미터
≤0.5 M salt concentration
0-100% aqueous soluble organic solvents
1 mL/min flow rate
10-30 °C temperature
120 bar max. pressure
기술
HPLC: suitable
길이 × I.D.
30 m × 7.8 mm
Matrix
silica particle platform
기질 활성군
diol phase
입자 크기
4 μm
공극 크기
250 Å pore size
작동 pH
2.5-7.5
분리 기술
size exclusion (SEC)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
The TSKgel SuperSW and UltraSW mAb columns consist of three specialized columns designed for the separation and analysis of monoclonal antibodies (mAb). While mAbs can be analyzed using many different modes of HPLC, size exclusion is best to determine the level of aggregation, dimer formation, and fragmentation, making it the best method for heterogeneity studies. TSKgel SuperSW mAb HR columns are optimized for high resolution analysis of mAb monomer and dimer; these 30 cm x 7.8 mm ID slica-based stainless steel columns offer reduced lot-to-lot variation, long column life, reduction of unspecified adsorption, and superior recovery of aggregates. The TSKgel SuperSW mAb columns utilize a unique pore-controlled technology, which produces a shallow calibration curve in the molecular weight region of a typical monoclonal antibody. The calibration curve for the TSKgel SuperSW mAb HR column is similar to that of the industry-leading TSKgel G3000SWxl column and has a shallower slope than the TSKgel UltraSW Aggregate column around the molecular weight range of gamma-globulin. This shallow calibration curve produces high resolution separations.
애플리케이션
TSKgel® superSW mAb HR HPLC column may be used in the separation of monoclonal antibodies using size exclusion chromatography (SEC).
물리적 형태
Shipped in 0.05% NaN3 and 0.1 M Na2SO4 in 0.1 M phosphate buffer, pH 6.7.
법적 정보
TSKgel is a registered trademark of Tosoh Corporation
가아드 컬럼
가장 최신 버전 중 하나를 선택하세요:
Alexander Rau et al.
mAbs, 13(1), 1902034-1902034 (2021-03-24)
Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the
Alexander Rau et al.
Molecular cancer therapeutics, 19(7), 1474-1485 (2020-05-21)
The frequent activation of HER3 signaling as a resistance mechanism to EGFR-targeted therapy has motivated the development of combination therapies that block more than one receptor tyrosine kinase. Here, we have developed a novel tetravalent, bispecific single-chain diabody-Fc fusion protein
null
문서
Size-exclusion chromatography (SEC) columns and ready-to-use standards facilitate method development and increase robustness of protein SEC methods.
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
